Progenics

CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) http://bit.ly/2T7nRPm 

Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer http://bit.ly/2T5xsGB 

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 http://bit.ly/2YBu5bp 

Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis http://bit.ly/2JSqbXM 

Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial http://bit.ly/2JAJ3t0 

Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer http://bit.ly/2X8nzwX 

Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI http://bit.ly/2J20dzf 

Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors http://bit.ly/2MYgnyN 

Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan http://bit.ly/2ZCdJAt 

Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer http://bit.ly/2IdGRbc 

Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting http://bit.ly/2Ws6TA9 

Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma http://bit.ly/2Ie6ZS1 

Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference http://bit.ly/30XoLBx 

Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting http://bit.ly/2VYqtUF 

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404 http://bit.ly/2WK6jtB 

Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update http://bit.ly/2vQ4hfH 

Data Presented at the 2019 American Urological Association (AUA) Annual Meeting Showcases Potential for Progenics’ PyL Imaging Agent http://bit.ly/2PNnesI 

Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9 http://bit.ly/2Wjlfin